Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H12F6N4O |
| Molecular Weight | 450.3366 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC2=C(C=CC(C#N)=C2C(F)(F)F)N1CC3=NOC(=N3)C4=CC=CC(=C4)C(F)(F)F
InChI
InChIKey=ZEDODTZELVBHTG-UHFFFAOYSA-N
InChI=1S/C21H12F6N4O/c1-11-7-15-16(6-5-13(9-28)18(15)21(25,26)27)31(11)10-17-29-19(32-30-17)12-3-2-4-14(8-12)20(22,23)24/h2-8H,10H2,1H3
| Molecular Formula | C21H12F6N4O |
| Molecular Weight | 450.3366 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:14:39 GMT 2025
by
admin
on
Mon Mar 31 23:14:39 GMT 2025
|
| Record UNII |
8TFL50092H
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
86620664
Created by
admin on Mon Mar 31 23:14:39 GMT 2025 , Edited by admin on Mon Mar 31 23:14:39 GMT 2025
|
PRIMARY | |||
|
1018971-95-3
Created by
admin on Mon Mar 31 23:14:39 GMT 2025 , Edited by admin on Mon Mar 31 23:14:39 GMT 2025
|
PRIMARY | |||
|
8TFL50092H
Created by
admin on Mon Mar 31 23:14:39 GMT 2025 , Edited by admin on Mon Mar 31 23:14:39 GMT 2025
|
PRIMARY | |||
|
GSK-971086
Created by
admin on Mon Mar 31 23:14:39 GMT 2025 , Edited by admin on Mon Mar 31 23:14:39 GMT 2025
|
PRIMARY | Official Title: A Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK971086 After a Single Dose and 7 Days of Repeat Dosing in Healthy Adult Male Volunteers; Purpose: This research study is the first administration of GSK971086 in humans. The purpose of this study is to assess the safety and tolerability of GSK971086, as well as, how much GSK971086 is in your blood after different doses. |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
SARM
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: GlaxoSmithKline; Mechanism of Action: Androgen receptor modulator; Highest Development Phase: No development reported for Muscular atrophy; Most Recent Event: 29 Apr 2011 No development reported - Phase-I for Muscular atrophy in USA (unspecified route)
|
